Answers are grounded in this paper and cite their sources.
Class III evidence has been augmented regarding vasopressor usage following acute SCI, however comparative benefits between vasopressors remain in need of elucidation due to small sample sizes and/or inadequate specificity to spine injury levels. Large prospective multicenter studies targeting age cohorts, and characterizing associated comorbidities and complication profiles, are of high priority in order to determine judicious use criteria of specific vasopressors for relevant subpopulations.
No takes yet. Share an insight, caveat, or question.
Yue et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: